Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

by divibasicbldev | May 28, 2024 | Press Releases

— PAS-004 inhibition of in vitro NRAS cell lines does not plateau in contrast to approved MEK inhibitors — — PAS-004 inhibition of in vitro NRAS cell lines is greater than selumetinib and binimetinib and similar to trametinib — — PAS-004...

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

by divibasicbldev | Apr 24, 2024 | Press Releases

– Initial safety, tolerability and biomarker data expected to be reported in 2H 2024 -SOUTH SAN FRANCISCO, Calif. and MIAMI, Fla., April 24, 2024 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the...

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

by divibasicbldev | Feb 13, 2024 | Press Releases

— Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy — — Plans to open three additional sites in Eastern Europe in the coming months — — Preliminary...

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

by divibasicbldev | Jan 8, 2024 | Press Releases

— Polymorph and Stereoisomer Patents when Issued Extend Portfolio to at least 2045 — — Polymorph and Stereoisomer Patent Filings Continue to Expand Patent Portfolio — SOUTH SAN FRANCISCO, Calif. and MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) —...

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

by divibasicbldev | Jan 2, 2024 | Press Releases

— PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials — — Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 – — Initial readout expected as early as Q3...